Skip to content

The Potency of Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension

Comparison of the Potency of Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension in Patients With Severe Preeclampsia During Caesarean Section

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05035472
Enrollment
80
Registered
2021-09-05
Start date
2023-01-01
Completion date
2023-12-31
Last updated
2021-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Effect

Keywords

Norepinephrine, Phenylephrine, Postspinal anesthesia hypotension, Preeclampsia, Cesarean section

Brief summary

The purpose of this study is to investigate the potency between prophylactic norepinephrine and phenylephrine boluses for postspinal anesthesia hypotension in patients with severe preeclampsia during caesarean section.

Detailed description

Preeclampsia, which affects 5% to 7% of patients, is a significant cause of maternal and neonatal morbidity and mortality. Because of constricted myometrial spiral arteries with exaggerated vasomotor responsiveness, though blood pressure in patients with preeclampsia are apparently higher than healthy patients, placental hypoperfusion is more common. Spinal anesthesia is still the preferred mode of anesthesia in patients with preeclampsia for cesarean section. In preeclampsia patients, spinal anesthesia improve intervillous blood flow (provided that hypotension is avoided) which contribute to increase placental perfusion. Even so, 17-26% patients with preeclampsia experienced postspinal anesthesia hypotension due to the extensive sympathetic block that occurred with spinal anesthesia. As a potential substitute drug for phenylephrine and ephedrine, norepinephrine has gained traction for use in patients undergoing cesarean section. However, the ED50 (prevent postspinal hypotension in 50% of patients) and ED90 of prophylactic norepinephrine bolus is still unknown. The purpose of this study is to investigate the potency between prophylactic norepinephrine and phenylephrine boluses for postspinal anesthesia hypotension in patients with severe preeclampsia during caesarean section.

Interventions

DRUGPhenylephrine

An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.

DRUGNorepinephrine

An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.

Sponsors

General Hospital of Ningxia Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* 18-45 years * Primipara or multipara * Singleton pregnancy ≥32 weeks * American Society of Anesthesiologists physical status classification II to III * Scheduled for cesarean section under spinal anesthesia

Exclusion criteria

* Baseline blood pressure ≥180 mmHg * Body height \< 150 cm * Body weight \> 100 kg or body mass index (BMI) ≥ 40 kg/m2 * Eclampsia or chronic hypertension * Hemoglobin \< 7g/dl * Fetal distress, or known fetal developmental anomaly

Design outcomes

Primary

MeasureTime frameDescription
The dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients1-15 minutes after spinal anesthesiaSystolic blood pressure (SBP) \< 80% of the baseline

Secondary

MeasureTime frameDescription
The incidence of post-spinal anesthesia hypotension1-15 minutes after spinal anesthesiaSystolic blood pressure (SBP) \< 80% of the baseline
The incidence of severe post-spinal anesthesia hypotension.1-15 minutes after spinal anesthesiaSystolic blood pressure (SBP) \< 60% of the baseline
The incidence of bradycardia.1-15 minutes after spinal anesthesiaHeart rate \< 60 beats/min.
The incidence of nausea and vomiting.1-15 minutes after spinal anesthesiaPresence of nausea and vomiting in patients after spinal anesthesia
APGAR score1 min after deliveryA= Appearance P=Pulse G=Grimace A=Attitude R=Respiration
pHImmediately after deliveryFrom umbilical arterial blood gases.
Partial pressure of oxygen (PO2)Immediately after deliveryFrom umbilical arterial blood gases.
Base excess (BE)Immediately after deliveryFrom umbilical arterial blood gases.
The incidence of hypertension.1-15 minutes after spinal anesthesiaSystolic blood pressure (SBP) \>120% of the baseline.

Contacts

Primary ContactXinli Ni, Dr.
xinlini6@nyfy.com.cn86-951-674-3252
Backup ContactYi Chen, M.D.
czzyxgp@163.com86-951-674-3252

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026